PMID- 34767960
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20220420
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Linking)
VI  - 27
IP  - 3
DP  - 2022 Mar
TI  - Obesity and insulin resistance: Pathophysiology and treatment.
PG  - 822-830
LID - S1359-6446(21)00479-7 [pii]
LID - 10.1016/j.drudis.2021.11.001 [doi]
AB  - The prevalence of obesity is a major cause of many chronic metabolic disorders, 
      including type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and 
      cancer. Insulin resistance is often associated with metabolic unhealthy obesity 
      (MUO). Therapeutic approaches aiming to improve insulin sensitivity are believed 
      to be central for the prevention and treatment of MUO. However, current 
      antiobesity drugs are reported as multitargeted and their insulin-sensitizing 
      effects remain unclear. In this review, we discuss current understanding of the 
      mechanisms of insulin resistance from the aspects of endocrine disturbance, 
      inflammation, oxidative, and endoplasmic reticulum stress (ERS). We then 
      summarize the antiobesity drugs, focusing on their effects on insulin 
      sensitivity. Finally, we discuss strategies for obesity treatment.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Tong, Yue
AU  - Tong Y
AD  - Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, School of Life 
      Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
FAU - Xu, Sai
AU  - Xu S
AD  - Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, School of Life 
      Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
FAU - Huang, Lili
AU  - Huang L
AD  - School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, 
      Australia. Electronic address: l.huang2@uq.edu.au.
FAU - Chen, Chen
AU  - Chen C
AD  - School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, 
      Australia. Electronic address: chen.chen@uq.edu.au.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211109
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - *Anti-Obesity Agents/therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - Insulin/metabolism
MH  - *Insulin Resistance
MH  - Obesity/drug therapy/metabolism
OTO - NOTNLM
OT  - Anti-obesity drugs
OT  - Insulin sensitivity
OT  - Obesity
EDAT- 2021/11/13 06:00
MHDA- 2022/04/21 06:00
CRDT- 2021/11/12 20:16
PHST- 2021/03/16 00:00 [received]
PHST- 2021/09/27 00:00 [revised]
PHST- 2021/11/01 00:00 [accepted]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
PHST- 2021/11/12 20:16 [entrez]
AID - S1359-6446(21)00479-7 [pii]
AID - 10.1016/j.drudis.2021.11.001 [doi]
PST - ppublish
SO  - Drug Discov Today. 2022 Mar;27(3):822-830. doi: 10.1016/j.drudis.2021.11.001. 
      Epub 2021 Nov 9.